Outcomes Research in Psoriasis and Psoriatic Arthritis Using Large Databases and Research Networks: A Report from the GRAPPA 2013 Annual Meeting

Armstrong, April W.; Gelfand, Joel M.; Garg, Amit

doi:10.3899/jrheum.140178

Cited by 6 publications

(2 citation statements)

References 32 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“… 12 Perhaps the most detrimental aspect of psoriasis is the concurrent physical comorbidities such as cardiovascular disease (CVD), obesity, diabetes, metabolic syndrome, inflammatory bowel disease (IBD), and psoriatic arthritis that contribute to decreased longevity. 13 – 16 …”

Section: Introductionmentioning

confidence: 99%

Current knowledge on psoriasis and autoimmune diseases

Ayala-Fontánez¹,

Soler²,

McCormick³

2016

PTT

118

View full text Add to dashboard Cite

Psoriasis is a prevalent, chronic inflammatory disease of the skin, mediated by crosstalk between epidermal keratinocytes, dermal vascular cells, and immunocytes such as antigen presenting cells (APCs) and T cells. Exclusive cellular “responsibility” for the induction and maintenance of psoriatic plaques has not been clearly defined. Increased proliferation of keratinocytes and endothelial cells in conjunction with APC/T cell/monocyte/macrophage inflammation leads to the distinct epidermal and vascular hyperplasia that is characteristic of lesional psoriatic skin. Despite the identification of numerous susceptibility loci, no single genetic determinant has been identified as responsible for the induction of psoriasis. Thus, numerous other triggers of disease, such as environmental, microbial and complex cellular interactions must also be considered as participants in the development of this multifactorial disease. Recent advances in therapeutics, especially systemic so-called “biologics” have provided new hope for identifying the critical cellular targets that drive psoriasis pathogenesis. Recent recognition of the numerous co-morbidities and other autoimmune disorders associated with psoriasis, including inflammatory bowel disease, multiple sclerosis, rheumatoid arthritis, and systemic lupus erythematosus suggest common signaling elements and cellular mediators may direct disease pathogenesis. In this review, we discuss common cellular pathways and participants that mediate psoriasis and other autoimmune disorders that share these cellular signaling pathways.

show abstract

Section: Introductionmentioning

confidence: 99%

Current knowledge on psoriasis and autoimmune diseases

Ayala-Fontánez¹,

Soler²,

McCormick³

2016

PTT

118

View full text Add to dashboard Cite

show abstract

“…Next, a group led by Joseph Merola (Boston) led a discussion of the Brigham Scalp Nail Inverse Palmoplantar Psoriasis Composite Index, as a complementary objective measure to the Psoriasis Area and Severity Index 13 . Finally, April Armstrong (Denver, Colorado, USA) led a discussion on large databases, including research networks, electronic medical records, and disease registries, that address real-world, clinically relevant dermatology questions 14 .…”

mentioning

confidence: 99%

Prologue: 2013 Annual Meeting of the Group for Research and Assessment of Psoriasis and Psoriatic Arthritis (GRAPPA)

Boehncke

Gladman

2014

J Rheumatol

View full text Add to dashboard Cite

The 2013 Annual Meeting of the Group for Research and Assessment of Psoriasis and Psoriatic Arthritis (GRAPPA) was held in July 2013 in Toronto, Canada, and attended by rheumatologists, dermatologists, and representatives of biopharmaceutical companies and patient groups. We introduce the articles that summarize the meeting: A summary of a GRAPPA-organized Fellows Symposium adjacent to the 2013 European Academy of Dermatology and Venereology meeting in Istanbul; at the GRAPPA meeting proper, proceedings of a trainee symposium, where rheumatology fellows and dermatology residents presented their research; a summary of experiences and perspectives of psoriasis and psoriatic arthritis (PsA) research of 8 patient research partners with PsA who were invited to participate as delegates. Other presentations and discussions included an interactive session on composite measures of disease severity and response, including voting by GRAPPA members; a 3 part update of basic/translational/clinical science, including new bone formation, enthesitis pathophysiology, and comorbidity monitoring; a 3 part dermatology update on psoriasis outcome measures, the Brigham Scalp Nail Inverse Palmoplantar Psoriasis Composite Index, and large-scale databases; a short summary of the ongoing GRAPPA effort to update treatment guidelines for PsA; updates on several GRAPPA educational and rheumatology-related projects; and a discussion of clinical criteria to identify inflammatory arthritis, enthesitis, dactylitis, and spondylitis as distinguished from non-inflammatory conditions.

show abstract